Lung cancer trials supported by drug industry stronger
And with no more bias than other studies
Denver–March 25, 2020– Lung cancer clinical trials supported by the pharmaceutical industry demonstrate no more bias compared to studies funded by other sources, according to a study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.
Clinical trials are expensive and often require funding from the pharmaceutical industry, but previous studies have revealed bias in clinical studies conducted by industry sponsors.
Pedro Aguiar Jr, M.D., M.Sc., Ph.D., M.B.A., Faculdade de Medicina do ABC Santo André, Brazil and his research team sought to determine if any bias existed among pharmaceutical-backed studies of therapies for non-small cell lung cancer patients. His group compared studies funded by drug companies with studies funded by other sources in terms of costs, reported results and strength of evidence.
Dr. Aguiar analyzed 477 studies focusing on non-small cell lung cancer that were published between 2012 and 2017. His analysis focused on 275 trials sponsored by the pharmaceutical industry and 202 funded by other sources. These studies included 85,328 patients — 64,434 in studies sponsored by the PI and 20,894 in studies with other funding sources.
Dr. Aguiar’s group assessed the risk of the following biases: randomization bias, allocation bias, performance bias, detection bias, attrition bias and reporting bias.
The authors write that industry interests may determine the types of research questions to be answered by clinical trials, as well as their experimental design. Previous studies suggest that even the results of some trials may be affected by industry-vested interests through several types of systematic errors such as reporting bias and violation of the uncertainty principle. The emphasis on the reporting and dissemination of positive results may favor a higher rate of reporting in comparison with negative ones.
Previous studies also suggest that even the results of some trials may be affected by industry-vested interests through several types of systematic errors such as reporting bias and violation of the uncertainty principle.
However, Aguiar’s analysis of clinical trials focusing on non-small cell lung cancer did not reveal any such bias.
“We found that studies funded by the pharmaceutical industry had stronger evidence, evaluated more innovative therapies and resulted in a higher proportion of open access manuscripts than studies supported by other funding sources,” Dr. Aguiar said. There was no significant difference regarding the reporting of experimental arm superiority between the two groups or the risk of bias, he added.
In the United States, the amount of money available for the National Institutes of Health to invest in one year is approximately $39 billion, whereas the amount spent by the pharmaceutical industry per year amounts to approximately $100 billion. During the five years considered in this review, the proportion of studies funded by the pharmaceutical industry increased from 49% in 2012 to 65% in 2017.
“In our study, the results of pharmaceutical industry-sponsored trials did not favor the experimental arms compared with other sources of funding and the reporting bias was considered low for almost 90% of all included studies,” Dr. Aguiar said.
About the JTO
The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit http://www.